Lilly’s Omvoh Achieves Over 90% Three-Year Steroid-Free Remission in Crohn’s Patients
More than 90% of Crohn’s disease patients treated with Lilly’s Omvoh maintained steroid-free remission through three years, with 92.4% clinical remission and 91.2% corticosteroid-free remission at 152 weeks. Omvoh also cut Crohn’s-related hospitalizations and surgeries by nearly 70% in weeks 12 to 52 versus placebo.
1. Durable Three-Year Steroid-Free Remission
Patients achieving endoscopic response at one year in the VIVID-1 program maintained high remission rates, with 92.4% in clinical remission and 91.2% remaining corticosteroid-free at 152 weeks of continuous monthly Omvoh dosing.
2. Significant Reduction in Complications
Omvoh reduced Crohn’s-related hospitalizations and surgeries by nearly half in the first 12 weeks (16.9 vs. 30.9 per 100 patient-years) and by nearly 70% during weeks 12 to 52 (4.5 vs. 14.0). In ulcerative colitis, treated patients experienced just 0.1 hospitalizations per 100 patient-years and zero surgeries over three years.
3. Consistent Safety Profile
The long-term safety profile remained consistent, with common adverse events from year one through year three (in ≥5% of responders) including COVID-19, nasopharyngitis and upper respiratory tract infections.
4. Ongoing Combination and Pediatric Trials
Lilly is advancing mirikizumab in combination studies with eltrekibart and LY4268989 in ulcerative colitis and Crohn’s disease, exploring incretin-based therapies in COMMIT-UC and COMMIT-CD trials, and conducting pediatric evaluations in both indications.